Oncolytics Biotech® Announces Matt Coffey, Ph.D. Will Not Return to CEO Role Following Medical Leave of Absence

Rhea-AI Summary

Oncolytics Biotech Inc. (NASDAQ: ONCY) announced that CEO and President Matt Coffey, Ph.D., will not return following his medical leave of absence due to ongoing health concerns. Coffey, who served the company for 25 years and was a co-founder, officially stepped down from his positions as CEO and Director.

Wayne Pisano, Chair of Oncolytics' Board of Directors and current Interim CEO, will maintain his temporary role until a new CEO is appointed. The company has initiated an immediate search for a new Chief Executive Officer to continue leading the development of pelareorep, their novel therapeutic agent for cancer treatment.

Under Coffey's leadership, pelareorep progressed from pre-clinical stages through successful Phase 2 studies for metastatic breast cancer and pancreatic cancer.

Positive

• Successful completion of Phase 2 studies for pelareorep in metastatic breast cancer and pancreatic cancer
• Immediate leadership transition plan in place with interim CEO

Negative

• Unexpected departure of long-term CEO and co-founder
• Potential disruption in company leadership during critical drug development phase

Search for Chief Executive Officer to commence immediately

SAN DIEGO and CALGARY, AB, Feb. 7, 2025 /PRNewswire/ -- Oncolytics Biotech^® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that Matt Coffey, Ph.D., President and Chief Executive Officer, will not return following a medical leave of absence and ongoing health concerns. After much thought and consideration, Dr. Coffey reached a decision that in the best interest of his family and Oncolytics Biotech Inc., he would officially step down as CEO and Director of the company.

"While we are saddened by his departure, we fully understand, respect, and support his decision. For the past 25 years, Matt has been invaluable to the organization and has led the development of pelareorep from pre-clinical through successful Phase 2 studies for metastatic breast cancer and pancreatic cancer. First as a co-founder and most recently as CEO, he has left an indelible fingerprint on the company and its employees. On behalf of the Board of Directors and all the dedicated employees of Oncolytics, we wish Matt good health and success, both now and in the future," said Wayne Pisano, Chair of Oncolytics' Board of Directors and Interim CEO. "We will now initiate a search for a Chief Executive Officer to lead the team as we work to bring Matt's vision of developing and making available a novel therapeutic agent (pelareorep) that addresses unmet needs in people undergoing cancer treatment." Wayne Pisano will remain Interim CEO until the new CEO is hired.

About Oncolytics Biotech Inc.

Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized Phase 2 studies in metastatic breast cancer and Phase 1 and 2 studies in pancreatic cancer. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.

Pelareorep has demonstrated synergies with multiple approved oncology treatments. Oncolytics is currently conducting and planning combination clinical trials with pelareorep in solid malignancies as it advances towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA. For further information, please visit: www.oncolyticsbiotech.com or follow the company on social media on LinkedIn and on X @oncolytics.

Company Contact

Jon Patton
Director of IR & Communication
jpatton@oncolytics.ca

Investor Relations for Oncolytics

Timothy McCarthy
LifeSci Advisors
+1-917-679-9282
tim@lifesciadvisors.com

Media Contact for Oncolytics

Michael Rubenstein
LifeSci Communications
mrubenstein@lifescicomms.com

Logo - https://mma.prnewswire.com/media/2408622/5157869/Oncolytics_Biotech_Inc_Logo.jpg

View original content to download multimedia:https://www.prnewswire.com/news-releases/oncolytics-biotech-announces-matt-coffey-phd-will-not-return-to-ceo-role-following-medical-leave-of-absence-302371699.html

SOURCE Oncolytics Biotech® Inc.

FAQ

Why did Matt Coffey step down as CEO of Oncolytics Biotech (ONCY)?

Matt Coffey stepped down as CEO of Oncolytics Biotech due to ongoing health concerns following a medical leave of absence.

Who is currently serving as interim CEO of Oncolytics Biotech (ONCY)?

Wayne Pisano, Chair of Oncolytics' Board of Directors, is currently serving as interim CEO until a new chief executive is appointed.

What are the main achievements of Matt Coffey during his tenure at ONCY?

During his 25-year tenure, Matt Coffey led the development of pelareorep from pre-clinical through successful Phase 2 studies for metastatic breast cancer and pancreatic cancer.

What is the current development status of ONCY's pelareorep?

Pelareorep has successfully completed Phase 2 studies for metastatic breast cancer and pancreatic cancer treatments.